You are using an outdated browser. Please upgrade your browser to improve your experience.


Ligand Summary
Alemtuzumab binds to CD52, an antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. A proportion of bone marrow cells, including some CD34+ cells, express variable levels of CD52. The proposed mechanism of action is antibody-dependent cellular-mediated lysis following cell surface binding of alemtuzumab to the leukemic cells.
Synonyms & Links
DrugCentral: 4909
LyCHI:  alemtuzumab

Target Activities